Cleveland Clinic researchers have found that nearly two-thirds of patients with HER2-positive metastatic breast cancer did not receive the guideline-recommended standard of care treatment between 2015 ...

This years 2026 ASCO Gastrointestinal Cancers Symposium was packed with practice-shaping data across colorectal and upper ...

Emerging immunotherapies and targeted therapies take aim at recently identified biomarkers ...

Advanced gastroesophageal adenocarcinoma (GEA) with HER2 positivity has long presented significant treatment challenges, with ...

Swiss pharma giant Roche Holding AG's RHHBY 2025 results were affected by currency headwinds. Sales totaled $74.4 billion, ...

Immunotherapy, targeted treatments, HIPEC, and new delivery options ...

Group results In 2025, Roche achieved sales growth of 7% (2% in CHF) to CHF 61.5 billion due to strong demand for pharmaceutical products and diagnostic solutions. The appreciation of the Swiss franc ...

Group sales grew by 7%1 at constant exchange rates (CER; 2% in CHF), driven by strong demand for medicines and diagnostic solutions.Sales in the fourth quarter increased by 8%, reflecting the positive ...

Sales rose 2 percent overall in 2025, driven by the strong performance of several oncology drugs, including greater uptake of ...

Duale also announced that The Nairobi Hospital, the long regarded as one of the country’s most exclusive private facilities ...